Mercury Pharmaceuticals

We are de-risking biomedical innovations, while turning biomedical knowledge into social and economic value.

Stay Informed!

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

10

Nov 2026

Qureight’s fibrosis imaging biomarker selected by Contineum Therapeutics as a secondary endpoint in Phase 2 PROPEL-IPF clinical trial

Qureight, an end-to-end imaging company providing enterprise-grade imaging and precision endpoints for clinical trials for lung and heart disease, and Contineum Therapeutics, Inc. (Contineum), a clinical-stage biopharmaceutical company pioneering differentiated small molecule therapies for inflammatory and fibrotic diseases with significant unmet need, today announced that Qureight’s Fibr8™ quantitative imaging biomarker is being used as a secondary endpoint in Contineum’s PROPEL-IPF Phase 2 clinical trial examining the safety and efficacy of PIPE-791, Contineum’s lead drug candidate, in idiopathic pulmonary fibrosis (IPF) patients.

Your Instagram photos may reveal more about loneliness than you think

9

Nov 2026

Your Instagram photos may reveal more about loneliness than you think

Researchers analyzing Instagram data from 415 US college students found that photographs, language, and online activity provided moderately useful indicators of subjective loneliness but were less informative about social isolation. Social loneliness was associated with lower interpersonal engagement, while emotional loneliness was linked to negative language, sad or angry facial expressions in profile photographs, and late-night posting.

Drinking 2–3 cups of coffee a day? A study of 495,000 adults links it to lower AF risk

9

Nov 2026

Drinking 2–3 cups of coffee a day? A study of 495,000 adults links it to lower AF risk

In a prospective study of 495,269 UK Biobank participants followed for approximately 13 years, researchers found that coffee consumption was associated with a 7% to 11% lower risk of atrial fibrillation (AF), with the strongest association observed at 2–3 cups daily. Tea consumption showed a more modest and less consistent association, with the authors reporting a 5% lower AF risk at 2–3 cups daily, although the observational findings cannot establish causation.

Historic redlining continues limiting healthy food access, study finds

21

Aug 2026

Historic redlining continues limiting healthy food access, study finds

Bad housing, high crime and poor schools are more important than transportation or income when it comes to accessing healthy food in neighborhoods historically subjected to "redlining" - the now-illegal practice once used to refuse loans, insurance or mortgages to people in certain neighborhoods that were disproportionately inhabited by racial and ethnicity minorities.

MERCURY trials

Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more

Cancer

Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more

Neuroscience

Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more

Mercury Pharmaceuticals

Why Us?

Strong experience in academic research and technology transfer makes us understand your goals and motivations as a technology originator.
Our experience in drug development from discovery to clinical and commercial stages makes us an insider player within the biopharmaceutical industry.
Smart approach to project management that helps speed up development stages and decision making.
Availability of own investment up to 2m€ per project allows us to reach the next value milestone.